Search results
Martin Metz is Professor of Dermatology with focus on pruritus research at the Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Germany. He received his medical education at the Free University of Berlin and the Humboldt University of Berlin.
Mast cells–key effector cells in immune responses. M Metz, M Maurer. Trends in immunology 28 (5), 234-241. , 2007. 389. 2007. Mast cells in the promotion and limitation of chronic inflammation. M Metz, MA Grimbaldeston, S Nakae, AM Piliponsky, M Tsai, SJ Galli. Immunological reviews 217 (1), 304-328.
Martin METZ | Cited by 19,139 | of Charité Universitätsmedizin Berlin, Berlin (Charité) | Read 396 publications | Contact Martin METZ
Abstract. Primary cutaneous T-cell lymphomas (CTCL), which include mycosis fungoides (MF) and Sézary syndrome (SS), are a group of lymphoproliferative disorders characterized by clonal accumulation of neoplastic T-lymphocytes in the skin.
Prof. Dr. med. Martin Metz. Head of Translational Research, MD. +49 30 450 518 419 (Office) +49 30 450 7 518 959. CBF, Hindenburgdamm 27. Charité - Universitätsmedizin Berlin. Institute of Allergology. Hindenburgdamm 27.
Oct 3, 2019 · In this small and short trial, no safety concerns regarding ligelizumab or omalizumab emerged. Conclusions: A higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelizumab therapy of 72 mg or 240 mg than with omalizumab or placebo.
Martin Metz. MD. Professor in the Department of Dermatology and Allergy, Head of Translational Research, and Deputy Head of Clinical Trials | Charité – Universitätsmedizin, Berlin, Germany. Biography. Martin Metz, MD, earned his medical degree from Humboldt University Berlin in Germany.
